

## Genotoxic Effects of Magnesium Deficiency in the Cardiovascular System and their Relationships to Cardiovascular Diseases and Atherogenesis

Burton M Altura<sup>1-5,\*</sup>, Nilank C Shah<sup>1,5</sup>, Gatha J Shah<sup>1</sup> and Bella T Altura<sup>1,3,5</sup>

<sup>1</sup>Department of Physiology and Pharmacology, The School of Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, New York, USA

<sup>2</sup>Department of Medicine, The School of Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, New York, USA

<sup>3</sup>Center for Cardiovascular and Muscle Research, The School of Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, New York, USA

<sup>4</sup>Bio-Defense Systems, Inc, Rockville Centre, New York, USA

<sup>5</sup>Oceana Biomedica, Estero, Florida, USA

\*Corresponding author: Altura BM, Department of Physiology and Pharmacology, State University of New Downstate Medical Center, Brooklyn, New York, USA; Tel: 718-270-2194; E-mail: baltura@downstate.edu

Rec date: May 23, 2016; Acc date: May 28, 2016; Pub date: May 31, 2016

Copyright: © 2016 Altura BM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

The authors present evidence for a novel, new hypothesis whereby magnesium deficiency (MgD) acts as a genotoxic agent which probably causes numerous, heretofore, unrecognized consequences, even over a short-term, on the physiological, molecular and biochemical machinery of cardiovascular tissues and cells. The end result of these genotoxic effects of MgD probably plays important roles in the etiology and generation of diverse cardiovascular diseases, atherosclerosis, inflammation, and strokes via alterations in the epigenome of cardiovascular tissues and cells. The importance of adequate water-borne and dietary levels of Mg is emphasized.

**Keywords:** Hypertension; Inflammation; Sphingolipids; Ceramide; Epigenetics

### Introduction

Over the past two decades, a considerable amount of research has taken place around the globe suggesting that a variety of chemicals and mutagens can produce genotoxic effects in multiple tissues and cells [1,2]. Genotoxicity connotes in genetics a destructive effect(s) on a cell's genetic material (i.e., DNA, RNA) thus potentially altering cell integrity, functions, and phenotype [1].

Genotoxins are, thus, mutagens. Some of these well-known genotoxins include radiation of different types and chemicals known to damage DNA. The end result of genotoxins result in modification of gene expression. Although numerous advances are being made about genotoxins, very little is known about the potential mechanisms involved in how genotoxins induce lesions in DNA and how these agents could result in chromosomal aberrations.

Recently, we have provided putative evidence that magnesium (Mg) - deficient environments can act like genotoxins on cardiovascular tissues and cells [3,4]. We provide, below, background, evidence, and our reasons for believing that magnesium deficiency (MgD) can result in genotoxicity in cardiovascular tissues and cells which probably play major roles in etiology of cardiac diseases, atherogenesis, inflammation, and stroke heretofore unexplained.

### Disturbances in Diets and Magnesium Deficiency Linked to Cardiac Diseases, Atherogenesis, Inflammation, and Stroke

Disturbances in diets are known to promote lipid deposition and accelerate the growth and transformation of smooth muscle and endothelial cells in the vascular walls of blood vessels and promote vascular and cardiac dysfunctions of several types; e.g., atherosclerosis, heart rhythm disturbances, decreases in cardiac ejection of blood, decreased force of ventricular and atrial contractility, decreases in arterial blood pressure, diminished venous return to the heart, cardiac tamponade, hypertension, strokes, sudden-cardiac death, myocardial infarctions, etc. [5-7]. A number of epidemiologic studies in North America and Europe have shown that people consuming Western-type diets are low in magnesium (Mg) content (i.e., 30-65% of the RDA for Mg) [7-11]. Most of these diets in the U.S.A. show that 60-80% of Americans are consuming 185-235 mg/day of Mg [6,10]. In 1900, in contrast, Americans were consuming 450-550 mg/day of Mg [6,8]. Low Mg content of drinking water, found in areas of soft-water and Mg-poor soil, is associated with high incidences of atherosclerosis, ischemic heart disease (IHD), coronary vasospasm, hypertension, and sudden-cardiac death (SCD) [6,8,12-17]. Both animal and human studies have demonstrated an inverse relationship between dietary intake of Mg and atherosclerosis [5,6,8,18-21]. The myocardial level of Mg has consistently been observed to be lower in subjects dying from IHD and SCD in soft-water areas than those in hard-water areas [5,6,8,12,13,15,18,22]. Mg plays essential roles in more than 500 enzymatic reactions in the body [23] and is required for all energy-generating reactions and oxidative phosphorylation [23,24].

More than 45 years ago, two of us demonstrated that  $Mg^{2+}$  behaves as a natural calcium channel blocker in both cardiac and vascular smooth muscle (VSM) cells [8,12,22,24-29]. We also showed in experimental animals that Mg behaves as a natural statin in that it can lower blood cholesterol and triglyceride levels [6,8,18,19,30] as well as act as a powerful vasodilator in the microcirculation and as a cardiac muscle relaxant [8,18,26,27,31-35]. Hypermagnesemic diets have been shown to ameliorate hypertension and atherogenesis [6,8,12,18,24,30,36-40]. Using sensitive and newly designed specific  $Mg^{2+}$  ion selective electrodes, our laboratories demonstrated that patients with hypertension, IHD, cardiac failure, strokes, diabetes mellitus types 1 and 2, pregnant women with gestational diabetes, renal-induced vascular changes (associated with elevated serum cholesterol), preeclampsia, hemorrhage, sickle cell anemia in children (and adults), and atherosclerosis exhibit significant reductions in serum/plasma/whole blood levels of ionized, but not total blood levels of Mg [6,8,18,40-62]. In addition, our laboratories have also shown that dietary deficiency in rabbits and rats causes vascular remodeling concomitant with atherogenesis (i.e., arteriolar wall hypertrophy and alterations in the matrices of the vascular walls) and hypertension [6,8,18,19,63-65]. These results could be considered the end result of genotoxic effects. Some of these results have very recently been observed to result in an acceleration of the aging process [66,67]. We believe these latter (genotoxic?) actions of MgD are also potentially the end result of low environmental levels of Mg in body fluids and dietary composition. Many of the pathophysiological and pathological molecular-biochemical alterations typically observed in tissues and cells in the aging process have been noted in MgD tissues and cells of the cardiovascular system by our group and some other investigators [6,8,12,18-21,24,30,36,63,65,67-78].

### **Magnesium Deficiency Activates NF- $\kappa$ B and Proto-Oncogenes, Increases $Ca^{2+}$ Uptake/Release, Releases Mitochondrial Cytochrome C, Releases Myocardial Enzymes, as Well as Produce Reactive Oxygen Species, Reactive Nitrogen Species and Nitric Oxide: Relationship to Oxidized LDL, Apoptosis, Ceramide, Cytokines, and Pathogenesis of Atherosclerosis and Hypertension**

Studies from our laboratories [8,37,69,79,80] and others [71,72,75] have demonstrated that genotoxic reactants such as reactive oxygen species (ROS), reactive nitrogen species and enzymes that generate nitric oxide (e.g., eNOS and iNOS) are generated in MgD states. All of these reactants along with movement of  $Ca^{2+}$  into the vascular smooth muscle (and endothelial) cells (as a consequence of MgD) [6,8,22,24-30,37,65,68,73,81,82] help to oxidize low density lipoprotein (LDL) in the blood and vascular walls to promote atherogenesis. The oxidized LDL (oxLDL) plays an important role in the pathogenesis of atherogenesis, to a large extent, through the elevated  $Ca^{2+}$  ion concentrations which contribute to blocking apoptosis of the macrophages (normally needed to cleanse the blood of debris and elevated lipids), thus, promoting uptake of oxLDL which then help to transform normal contractile VSM cells to non-contractile new VSM cell phenotypes which act to produce and synthesize a variety of chemicals needed for the atherogenic process. Atherosclerosis is a complicated inflammatory disorder that involves activation, proliferation, changes in cell phenotypes (e.g., contractile VSM cells to non-contractile synthetic cell machines) and survival of macrophages

[7,83]. In addition, for atherogenesis and hypertension to develop, pathways for activation of NF- $\kappa$ B and proto-oncogenes must perforce take place. MgD results in all of the latter in intact and in situ VSM and myocardial cells, at least in experimental animals [3,4,11,67,70,73,79,81,82].

The pathophysiology of hypertensive vascular disease involves vascular remodeling via the proliferation and migration of VSM cells [7,84]. Low  $[Mg^{2+}]_0$  environments have been shown by our group [6,8,18,19,65,73] and others [66,75] to promote proliferation and migration of VSM cells. Moreover, our laboratories have demonstrated that vascular remodeling and inflammation, at the microcirculatory level, is seen in rabbits and rats whom are given diets low in Mg [6,8,11,18,19,37,63-65] which are similar to the low dietary levels of people now residing in North America and Europe. These pathological changes clearly are a consequence of the genotoxic effects of MgD. In cultured VSM and human endothelial cells, low  $Mg^{2+}$  results in the generation and release of cytokines, chemokines, and ceramides that are needed to mediate inflammatory events required for the initiation of atherogenesis [3,4,6,8,11,18,67,68,70,73,74,79,81]. These events were demonstrated to involve activation of NF- $\kappa$ B via ROS, NOS, and nitric oxide synthase [6,8,11,67,69,70,73,79-82]. As we predicted, inhibition of cytokine release, inhibition of telomerase downregulation, inhibition of ceramide generation, inhibition of myocardial enzyme release (i.e., lactic acid dehydrogenase, creatine kinase, troponin T), inhibition of NF- $\kappa$ B activation, or inhibition of activation of proto-oncogenes, in cultured VSM cells with excess Mg, were found to prevent or ameliorate the toxic vascular and cardiac effects of MgD [3,4,6,11,67,69,70,73,74,79,81].

### **Magnesium Deficiency Results in Oxidation and Fragmentation of DNA, Downregulation of Telomerase, And Increased Levels of Ceramide and P53: Relation to Cellular Mutations and Epigenetics**

Two years ago, our laboratories demonstrated, for the first time, that 21 days of low dietary Mg intake in living rats, results in a downregulation of telomerase in cardiac and VSM muscle [67]. These exciting results appeared to be closely related to fragmentation and oxidation of DNA, increased cellular levels of ceramide and increased cellular levels of the tumor suppressor gene, p53 [3,67,70,74,79]. Our studies pointed to a sizeable cross-talk among telomerase, neutral sphingomyelinase (N-SMase) and p53 in rat cardiac and peripheral vascular smooth muscle exposed to short-term MgD [3,67]. We suggested that our results would be compatible with the idea that even short-term MgD could cause alterations of the epigenome in diverse cell types leading to mutations of cardiac, vascular, and endothelial cells in aging and atherogenesis. Two years ago, we suggested ways in which this hypothesis can be tested [67]. Recently, Thakore et al. [2] (among others) have stated "site-specific alterations of the epigenomic landscape in eukaryotic cells are a powerful strategy for interrogating the mechanistic relationships among chromatin state, gene regulation, and cell phenotype".

### **Importance of Mg-supplemented Drinking Water and Beverages: Role of Adequate Mg Intake to Overcome and Prevent Genotoxic Effects of Mg Deficiency**

Over the past two-plus decades, our laboratories have demonstrated, at least experimentally, that we can overcome all of the genotoxic cardiovascular actions (i.e., physiological, biochemical and

molecular) of Mg deficiency in rats, rabbits and mice by either supplementing drinking water with Mg or adding Mg to the diets fed to the animals [3,4,6,8,18,19,67,68,74,79,81]. Our results, so far, bolster the idea that water intake (e.g., from tap waters, well waters, bottled waters, beverages using tap/well/spring waters, or desalinated waters) in humans should contain at least 25-40 mg/liter/day of Mg<sup>2+</sup> [85]. The latter inclusion in our diets should go a long-way towards the prevention of cardiovascular diseases and ameliorate the atherosclerotic and inflammatory aspects of the aging process of bodily tissues and cells in humans worldwide. Interestingly, on the basis of our work (and some others), the World Health Organization has taken our recommendations seriously, for the first time [86]. Lastly, this has led Israel to supplement its desalinated drinking water, in the Southern part of the country, with Mg<sup>2+</sup> to determine the cardiovascular benefits of this approach over a 5-year period [86].

## Conclusion

Herein we review and present evidence for a novel, new hypothesis on why MgD can act as a genotoxic agent and potentially cause numerous adverse effects, even over a short-term, on the physiological, molecular and biochemical machinery of cardiovascular tissues and cells. The end result of such genotoxic effects of MgD probably plays important roles in the etiology and generation of diverse cardiovascular diseases, atherosclerosis, inflammation, and strokes via alterations in the epigenome of these cardiovascular entities. The importance of adequate waterborne and dietary levels of Mg is emphasized.

## Acknowledgements

Some of the original experimental and clinical studies mentioned in the above were supported, in part, by research grants from The N.I.H. (National Heart Lung, and Blood Institute, National Institute on Drug Abuse, The National Mental Health Institute, and The National Institute on Alcoholism and Alcohol Abuse to B.M.A and B.T.A.). We also received unrestricted grant support from several pharmaceutical companies, including CIBA-GEIGY, SANDOZ, Bayer, Pfizer, and The Upjohn Co.

## References

1. Sierra LM, Gaivao I (2014) Genotoxicity and DNA Repair. New York.
2. Thakore PI, Black JB, Hilton IB, Gersbach CA (2016) Editing the epigenome: technologies for programmable transcription and epigenetic modulation. *Nature Meth* 13: 127-137.
3. Altura BM, Shah NC, Li Z, Jiang XC, Zhang A, et al. (2010) Short-term magnesium deficiency upregulates sphingomyelinase synthase and p53 in cardiovascular tissues and cells: relevance to de novo synthesis of ceramide. *Am J Physiol Heart Circ Physiol* 299: H2046-H2055.
4. Altura BM, Shah NC, Shah GJ, Li W, Zhang A, et al. (2013) Magnesium deficiency upregulates sphingomyelinases in cardiovascular tissues and cells: cross-talk among proto-oncogenes, Mg<sup>2+</sup>, NF- $\kappa$ B and ceramide and their potential relationships to resistant hypertension, atherogenesis and cardiac failure. *Int J Clin Exp Med* 6: 861-879.
5. Seelig MS (1980) Magnesium Deficiency in the Pathogenesis of Disease. New York.
6. Altura BM, Altura BT (2007) Magnesium: forgotten mineral in cardiovascular biology and angiogenesis. In *New Perspectives in Magnesium Research*. New York.
7. Kumar V, Abbas AK, Aster JC (2015) Robbins and Cotran Pathologic Basis of Disease. 9th edtn. Philadelphia.
8. Altura BM, Altura BT (1995) Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. *Cell Mol Biol Res* 41: 347-359.
9. Ford ES, Mokdad AH (2003) Dietary magnesium intake in a national sample of US adults. *J Nutr* 133: 2879-2882.
10. Mosfegh A, Goldman J, Abuja J, Rhodes D, La Comb R (2009) What We Eat in America. NHANES 2005-2006: usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus and Magnesium. US Department of Agricultural Research.
11. Altura BM, Shah NC, Shah GJ, Perez-Albela JL, Altura BT (2016) Magnesium deficiency results in oxidation and fragmentation of DNA, down regulation of telomerase activity, and ceramide release in cardiovascular tissues and cells: potential relationship to atherogenesis, cardiovascular diseases and aging. *Int J Diabetol Vasc Dis Res* 4: 1-5.
12. Altura BM, Altura BT (1984) New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. *Magnesium* 4: 226-244.
13. Marier JR, Neri LC (1985) Quantifying the role of magnesium in the interrelationship between human mortality/morbidity and water hardness. *Magnesium* 4: 53-59.
14. Leary WP (1986) Content of magnesium in drinking water and deaths from ischaemic heart disease in white South Africans. *Magnesium* 5: 53-59.
15. Chipperfield B, Chipperfield JR (1979) Relation of myocardial metal concentrations to water hardness and death-rates from ischaemic heart disease. *Lancet* 2: 709-712.
16. Marx A, Neutra RR (1997) Magnesium in drinking water and ischaemic heart disease. *Epidemiol Rev* 19: 258-272.
17. Rubenowitz E, Molin I, Axelsson G, Rylander R (2000) Magnesium in drinking water in relation to morbidity and mortality from acute myocardial infarction. *Epidemiology* 11: 416-421.
18. Altura BM, Altura BT (1995) Magnesium in cardiovascular biology. *Sci Am Sci Med* 2: 28-37.
19. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, et al. (1990) Magnesium dietary intake modulates blood lipid levels and atherogenesis. *Proc Natl Acad Sci* 87: 1840-1844.
20. Ouchi Y, Tabata RE, Stegiopoulos K, Sato K, Hatori A, et al. (1990) Effect of dietary magnesium on development of atherosclerosis in cholesterol-fed rabbits. *Arteriosclerosis* 10: 732-737.
21. King JL, Miller Rj, Blue JP, O'Brien WD Jr, et al. (2009) Inadequate dietary magnesium intake increases atherosclerosis plaque development in rabbits. *Nutr Res* 29: 343-349.
22. Turlapaty PDMV, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. *Science* 308: 198-200.
23. de Baaij JHF, Hoenderop JG, Bindels RJ (2015) Magnesium in man: Implications for health and disease. *Physiol Rev* 95: 1-46.
24. Altura BM, Altura BT (1984) Magnesium, electrolyte transport and coronary vascular tone. *Drugs* 28: 120-142.
25. Altura BM, Altura BT (1971) Influence of magnesium on drug-induced contractions and ion content in rabbit aorta. *Am J Physiol* 220: 938-944.
26. Altura BM, Altura BT (1974) Magnesium and contraction of arterial smooth muscle. *Microvasc Res* 7: 5-16.
27. Altura BM, Altura BT (1978) Magnesium and vascular tone and reactivity. *Blood Vessels* 13: 5-15.
28. Altura BM, Altura BT (1981) Role of magnesium ions in contractility of blood vessels and skeletal muscles. *Magnesium Bulletin* 3: 102-114.
29. Altura BM, Altura BT (1981) General anesthetics and magnesium ions as calcium antagonists. In: *New Perspectives on Calcium Antagonists*. Am Physiol Soc pp: 131-145.
30. Altura BM, Altura BM (1984) Interactions of Mg and K on blood vessels-Aspects in view of hypertension: review of present status and findings. *Magnes: Exp Clin Res* 3: 175-195.

31. Friedman HS, Nguyen TN, Mokraoui AM, Barbour RL, Murakawa T, et al. (1987) Effects of magnesium chloride on cardiovascular hemodynamics in the neurally intact dog. *J Pharmacol Exp Ther* 243: 126-130.
32. Nagai I, Gebrewold A, Altura BT, Altura BM (1988) Magnesium salts exert direct vasodilator effects on rat cremaster muscle microcirculation. *Arch Int Pharmacodyn Ther* 294: 194-214.
33. Nishio A, Gebrewold A, Altura BT, Altura BM (1988) Comparative effects of magnesium salts on reactivity of arterioles and venules to constrictor agents. An in situ study on microcirculation. *J Pharmacol Exp Ther* 246: 859-865.
34. Nishio A, Gebrewold A, Altura BT, Altura BM (1989) Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules. *Arch Int Pharmacodyn Ther* 298: 139-165.
35. Altura BM, Altura BT (1985) New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. II. Experimental aspects. *Magnesium* 4: 245-271.
36. Luthringer C, Rayssiguier Y, Gueux E, Berthelot A (1988) Effect of moderate magnesium deficiency on serum lipids, blood pressure and cardiovascular reactivity in normotensive rats. *Br J Nutr* 59: 243-250.
37. Altura BM, Altura BT (1990) Magnesium and the cardiovascular system: experimental and clinical aspects. *Metals in Biological Systems* 26: 359-416.
38. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A (2000) Magnesium : an update on physiological, clinical and analytical aspects. *Clin Chim Acta* 294: 1-26.
39. Altura BT, Altura BM (1991) Measurement of ionized magnesium in whole blood, plasma and serum with a new ion-selective electrode in healthy and diseased human subjects. *Magn Trace Elem* 10: 90-98.
40. Altura BT, Shirey TL, Young CC, Hiti J, Dell'Orfano K, et al. (1992) A new method for the rapid determination of ionized Mg<sup>2+</sup> in whole blood, serum and plasma. *Methods Find Exp Clin Pharmacol* 14: 297-304.
41. Handwerker SM, Altura BT, Royo B, Altura BM (1993) Ionized magnesium and calcium levels in umbilical cord serum of pregnant women with transient hypertension during labor. *Am J Hypertens* 6: 542-545.
42. Altura BM, Altura BT (1994) Role of magnesium in alcohol-induced hypertension and strokes as probed by in vivo television microscopy, digital image microscopy, optical spectroscopy, <sup>31</sup>P-NMR spectroscopy and a unique magnesium ion-selective electrode. *Alcohol Clin Exp Res* 18: 1057-1068.
43. Markell MS, Altura BT, Barbour RL, Altura BM (1993) Ionized and total magnesium levels in cyclosporin-treated renal transplant recipients: relationship with cholesterol and cyclosporin levels. *Clin Sci* 85: 315-318.
44. Markell MS, Altura BT, Sarn Y, Delano BG, Hudo O, et al. (1993) Deficiency of serum ionized magnesium in patients receiving hemodialysis or peritoneal dialysis. *ASAIO J* 39: M801-M804.
45. Resnick LM, Altura BT, Gupta RK, Alderman MH, Altura BM (1993) Intracellular and extracellular magnesium depletion in type 2 diabetes (non-insulin-dependent) diabetes mellitus. *Diabetologia* 36: 767-770.
46. Altura BM, Lewenstam A (1994) Unique Magnesium -Sensitive Ion Selective Electrodes. *Scand J Clin Lab Invest* 54: 1-100.
47. Altura BM, Altura BT (1996) Role of magnesium in pathophysiological processes and the clinical utility of magnesium ion-selective electrodes. *Scand J Clin Lab Invest* 56: 211-234.
48. Bardicef M, Bardicef O, Sorokin Y, Altura BM, Altura BT, et al. (1995) Extracellular and intracellular magnesium depletion in pregnancy and gestational diabetes. *Am J Obst Gynecol* 172: 1009-1013.
49. Altura BT, Memon ZI, Zhang A, Cracco RQ, Altura BM (1997) Low levels of serum ionized magnesium found in patients early after stroke which results in rapid elevation in cytosolic free calcium and spasm in cerebral vascular smooth muscle cells. *Neurosci Lett* 230: 37-40.
50. Resnick LM, Bardicef D, Altura BT, Alderman MH, Altura BM (1997) Serum ionized magnesium: Relation to blood pressure and racial factors. *Am J Hypertens* 10: 1420-1424.
51. Seelig MS, Altura BM (1997) How best to determine magnesium requirement: Need to consider cardiotherapeutic drugs that affect its retention. *J Am Coll Nutr* 16: 4-6.
52. Altura BM, Altura BT (1999) Association of alcohol in brain injury, headaches and stroke with brain tissue and serum levels of ionized magnesium: A review of recent findings and mechanisms of action. *Alcohol* 19: 119-130.
53. Muneyyyrici-Delale O, Nacharaju VL, Jalou S, Rahman M, Altura BM, et al. (2001) Divalent cations in women with PCOS: Implications for cardiovascular disease. *Gynecol Endocrinol* 15: 198-201.
54. Handwerker SM, Altura BT, Jones KY, Altura BM (1995) Maternal-fetal transfer of ionized serum magnesium during stress of labor and delivery: a human study. *J Am Coll Nutr* 14: 376-381.
55. Scott VL, DeWolf AM, Kang Y, Altura BT, Virji MA, et al. (1996) Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication. *Liver Transpl Surg* 2: 343-347.
56. Fogh-Andersen N, Altura BM, Altura BT, Sigaard-Andersen O (1996) Changes in plasma ionized calcium and magnesium in blood donors after donation of 450 ml blood. Effects of hemodilution and Donnan equilibrium. *Scand J Clin Lab Invest* 56: 245-250.
57. Djurhuus S, Henriksen JE, Kligaard NA, Blaabjerg O, Thye-Ron P, et al (1999) Effect of moderate improvement in metabolic control on magnesium and lipid concentrations in patients with type I diabetes. *Diabetes Care* 22: 546-554.
58. Djurhuus S, Kligaard NA, Pedersen KK, Blaabjerg O, Altura BM, et al. (2001) Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type I diabetes. *Metabolism* 50: 1409-1417.
59. Altura RA, Wang WC, Wynn L, Altura BM, Altura BT (2002) Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. *J Pediatr* 140: 565-569.
60. Zehtabchi S, Sinert R, Rinnert S, Chang B, Hennis R, et al. (2004) Serum ionized magnesium levels and ionized calcium to magnesium ratios in adult patients with sickle cell anemia. *Am J Hematol* 77: 215-222.
61. Apostol A, Apostol R, Ali E, Choi A, Ehsuni N, et al. Cerebral spinal fluid and serum ionized magnesium and calcium levels in preeclamptic women during administration of magnesium sulfate. *Fertil Steril* 94: 276-282.
62. Altura BM, Altura BT, Gebrewold A, Ising H, Gunther T (1984) Magnesium deficiency and hypertension: correlation between magnesium deficiency diet and microcirculatory changes in situ. *Science* 223: 1315-1317.
63. Altura BM, Altura BT, Gebrewold A, Gunther T, Ising H (1992) Noise-induced hypertension and magnesium: relationship to microcirculation and calcium. *J Appl Physiol* 72: 194-202.
64. Altura BM, Altura BT (1996) Magnesium as an extracellular signal in cardiovascular pathobiology. *J Jap Soc Magnes Res* 15: 17-32.
65. Kililea DW, Ames BN (2008) Magnesium deficiency accelerates cellular senescence in cultured human fibroblasts. *Proc Natl Acad Sci* 105: 5768-5773.
66. Shah NC, Shah GJ, Li Z, Jiang XC, Altura BT, et al. (2014) Short-term magnesium deficiency downregulates telomerase, upregulates neural sphingomyelinase and induces oxidative DNA damage in cardiovascular tissues : relevance to atherogenesis, cardiovascular diseases and aging. *Int J Clin Exp Med* 7: 497-514.
67. Altura BM, Gebrewold A, Altura BT, Brautbar N (1996) Magnesium depletion impairs carbohydrate and lipid metabolism and cardiac bioenergetics and raises myocardial calcium content in vivo: relationship to etiology of cardiac diseases. *Biochem Mol Biol Int* 40: 1183-1190.
68. Wu F, Altura BT, Gao J, Barbour RL, Altura BM (1984) Ferrylmyoglobin formation induced by acute magnesium deficiency in perfused rat heart causes cardiac failure. *Biochim Biophys Acta* 1225: 158-164.
69. Altura BM, Gebrewold A, Zhang A, Altura BT (2003) Low extracellular magnesium induces lipid peroxidation and activation of nuclear factor- $\kappa$ B in canine cerebral vascular smooth muscle: possible relation to traumatic brain injury and strokes. *Neurosci Lett* 341: 189-192.

70. Dickens BF, Weglicki WB, Li YS, Mak IT (1992) Magnesium deficiency invitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. *FEBS Lett* 311: 187-191.
71. Weglicki WB, Mak IT, Kramer JH, Dickens BF, Cassidy MM, et al. (1996) Role of free radicals and substance P in magnesium deficiency. *Cardiovasc Res* 31: 677-682.
72. Altura BM, Kostellow AB, Zhang A, Li W, Morrill GA, et al. (2003) Expression of nuclear factor-kB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg<sup>2+</sup> in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis, and stroke. *Am J Hypertens* 16: 701-707.
73. Altura BM, Shah NC, Jiang XC, Li Z, Perez-Albela JL, et al. (2009) Short-term Magnesium deficiency results in decreased levels of serum sphingomyelin, lipid peroxidation, and apoptosis in cardiovascular tissues. *Am J Physiol Heart Circ Physiol* 297: H86-H92.
74. Mazur A, Maier JA, Rock, Gueux E, Nowacki W, et al. (2007) Magnesium and the inflammatory response: potential physiopathological implications. *Arch Biochem Biophys* 458: 48-56.
75. Emila S, Swaminathan S (2013) Role of magnesium in health and disease. *J Exp Sci* 4: 32-43.
76. Long S, Romani AM (2014) Role of cellular magnesium in human disease. *Austin J Nutr Food* 2.
77. Grober U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. *Nutrients* 7: 8199-8226.
78. Shah NC, Liu JB, Iqbal J, Hussain M, Jiang XC, et al. (2011) Mg deficiency results in modulation of serum lipids, glutathione, and NO synthase isozyme activation in cardiovascular tissues: relevance to de novo synthesis of ceramide, serum Mg and atherogenesis. *Int J Clin Expe Med* 4: 103-118.
79. Yang ZW, Gebrewold A, Nowakowski M, Altura BT, Altura BM (2000) Mg<sup>2+</sup>-induced endothelium -dependent relaxation of blood vessels and blood pressure lowering: role of NO. *Am J Physiol Regul Comp Physiol* 278: R628-R639.
80. Altura BM, Li W, Zhang A, Zheng T, Shah NC, et al. (2016) The expression of platelet-activating factor is induced by low extracellular Mg<sup>2+</sup> in aortic, cerebral and neonatal coronary vascular smooth muscle; cross-talk with ceramide production, NF-kB and proto-oncogenes: Possible links to atherogenesis and sudden cardiac death in children and infants, and aging; Hypothesis , Review and Viewpoint. *Int J Cardiol Res* 3: 47-67.
81. Altura BM, Shah NC, Shah GJ, Perez-Albela JL, Altura BT (2016) Insights into the possible mechanisms by which platelet-activating factor and PAF-receptors function in vascular smooth muscle in magnesium deficiency and vascular remodeling: possible links to atherogenesis, hypertension and cardiac failure. *Int J Cardiol Res* 3: 1-3.
82. Majno G, Jorris I (1996) *Cells, Tissues, and Disease*. 2nd edtn. Oxford University Press.
83. Lilly LS (2012) *Pathophysiology of Heart Disease*. 5th edtn. Philadelphia.
84. Altura BM, Altura BT (2009) Atherosclerosis and magnesium. In *Calcium and Magnesium in Drinking Water*. Geneva. 75-81.
85. *Calcium and Magnesium in Drinking Water*. Public Health Significance. Geneva, World Health Organization.
86. Siegel J (2012) Gov't okays adding magnesium to drinking water. "The Jerusalem Post".